期刊文献+

30例乳腺癌患者级联激活的免疫细胞治疗后细胞免疫功能变化 被引量:4

Changes of Cellular Immune Function in 30 Cases of Patients with Breast Cancer After Therapy of CAPRI
下载PDF
导出
摘要 目的观察乳腺癌患者CAPRI细胞治疗前后T淋巴细胞亚群的变化及其临床意义.方法采用流式细胞术(FCM)检测30例乳腺癌患者化疗6周期后接受CAPRI细胞治疗1周期前后的淋巴细胞亚群并进行对比研究.结果接受CAPRI细胞治疗1周期后乳腺癌患者的外周血中的CD3+细胞、CD4+细胞、NK细胞的数量与接受CAPRI细胞治疗前相比均有较明显的提高(P<0.05),而CD8+细胞的数量与接受CAPRI细胞治疗前相比没有较明显的改变(P>0.05).结论乳腺癌患者化疗结束后应用CAPRI细胞治疗对乳腺癌患者的细胞免疫功能具有明显改善作用. Objective To observe the changes of T-lymphocyte subsets of patients with breast cancer before and after therapy of CAPRI.Method By flow cytometry(FCM),we detected the changes of T-lymphocyte subsets of 30 cases of patients with breast cancer who received 6 cycles of chemotherapy before and after one cycle of therapy of CAPRI and performed comparative studies.Result Compared to pretherapy of CAPRI,after one cycle of therapy of CAPRI,there was significant increase in the number of CD3+ cells,CD4+ cells,NK cells in the peripheral blood of the patients with breast cancer(P0.05),and there was no significant change in the number of CD8+ cells in the peripheral blood of the patients(P0.05).Conclusions The therapy of CAPRI can improve significantly the cellular immune function of the patients with breast cancer after chemotherapy.
出处 《昆明医学院学报》 2009年第11期68-71,共4页 Journal of Kunming Medical College
基金 昆明医学院研究生创新基金资助项目(KM2008J13)
关键词 乳腺癌 级联激活的免疫细胞 细胞免疫 生物治疗 Breast cancer CAPRI Cellular immunity Biotherapy
  • 相关文献

参考文献12

  • 1LEGHA S S. Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy [J ]. Semin Oncol , 1997, (Supp124) : S39 - 43. 被引量:1
  • 2PARKIN D M,BRAY F,FERAY J,et al. Global cancer statistics [J]. 2002.CA Cancer J Clin,2005,55:74 - 108. 被引量:1
  • 3SWENSON K K, HENLY S J, SHAPIRO A C,et al. Interventions to prevent loss of bone mineral density in women receiving chemotherapy for breast cancer[ J ]. Clin J Oncol Nurs, 2005,9(2) : 177 - 184. 被引量:1
  • 4WANK, RUDOLF. Use of stimulated peripheral blood mononuclear ceils for treating cancerous diseases :Germany, WO 02/087612 A2[ P ].2002 - 07 - 11. 被引量:1
  • 5KHAYAT D, BERNARD MARTY C, MERIC J B,et al. Biochemotherapy for advanced melanoma:maybe it is real [J]. J Clin Oncol,2002,20(10) :2411 - 2414. 被引量:1
  • 6VOGEL C L,COBLEIGH M A,TRIPATHY D,et al. First-line herceptin monotherapy in metastatic breast cancer [ J ]. Oncology, 2001,10(61 Suppl S2) : 37 - 42. 被引量:1
  • 7KOWOLIK C M,TOPP M S,GONZALEZ S,et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T ceils [J]. Cancer Res, 2006,66 (22) : 10995 - 11004. 被引量:1
  • 8JARVINEN T A, LIU E T. Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes-molecular basis for combination chemotherapy in cancer [J]. Curr Cancer Drug Targets,2006,6 (7): 579 - 602. 被引量:1
  • 9SATTO T, SHIMODA K, KINO SHTTA T, et al. Prediction of operative mortality based on impairment of ho st defense system in patient with esophageal cancer[J]. J Surg Oncol, 1993,52:1 - 2. 被引量:1
  • 10TSUTSUI S H, MO RTTAM, KUWANO H, et al. Influence of preoperative treatment and surgical operation on immune function of patient with esophageal carcinoma [J]. J Surg Oncol,1992,49:176 - 177. 被引量:1

同被引文献21

引证文献4

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部